Transplantation: Tofacitinib safe and effective in renal transplant recipients

@article{Myrvang2012TransplantationTS,
  title={Transplantation: Tofacitinib safe and effective in renal transplant recipients},
  author={Helene K Myrvang},
  journal={Nature Reviews Nephrology},
  year={2012},
  volume={8},
  pages={432-432}
}
The oral Janus kinase inhibitor, tofacitinib, is safe and effective in low-to-moderate risk de novo renal transplant recipients when compared with ciclosporin shows a new phase 2b study published in the American Journal of Transplantation. “Rejection rates were low with better preservation of renal function, so these results are potentially an important advance for calcineurin-inhibitor-free regimens”, says researcher Flavio Vincenti. Although calcineurin inhibition remains the cornerstone of… 

Tofacitinab in renal transplantation.

  • M. Zand
  • Medicine, Biology
    Transplantation reviews
  • 2013

Targeting kinases: a new approach to treating inflammatory rheumatic diseases.

  • D. Simmons
  • Biology, Chemistry
    Current opinion in pharmacology
  • 2013

Attenuating Janus Kinases (JAK) by Tofacitinib Effectively Prevented Psoriasis Pathology in Various Mouse Skin Inflammation Models

The results suggest the mechanism of action of tofacitinib is likely due to its ability to block multiple cytokines and attenuate immune response that contribute to the positive clinical efficacy in psoriasis.

Selective JAK inhibitors.

X-ray co-crystal structures reveal the molecular reasons for the observed biochemical selectivity of JAK kinases, and suggest a very promising future in the treatment of oncology, immune and inflammatory diseases.

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012

This review attempts to provide an update of the recent patent literature of more selective JAK2 or JAK3 compounds and shows that the vast majority of compounds are based on classic ATP-competitive kinase inhibitor heterocycles.

References

Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

  • F. VincentiH. Tedesco Silva G. Chan
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2012
Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side‐effects at the doses evaluated.